Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Integrated multi-omics analyses and functional validation reveal TTK as a novel EMT activator for endometrial cancer

Fig. 2

Aberrant TTK overexpression is linked to aggressive phenotypes in EC. A Differential analysis of TTK expression in TCGA pan-cancer. B, C Differential analysis of TTK expression in TCGA EC patients, as divided by tumor stage (B, left panel: stage I, stage II, stage III, and stage VI), tumor grade (B, right panel: G1, G2, and G3), as well as the histologic type (C; EEC: endometrioid; serous; mixed-type). D The GEO database was used to show increased TTK expression in serous ECs. The comparison was conducted using Wilcoxon tests. *P < 0.05, **P < 0.01, ***P < 0.001. E An immunohistochemical picture from the HPA database demonstrates high TTK protein expression in EC tissues than in adjacent normal tissues. F Results of subcellular localization of TTK protein, green indicates target protein, blue indicates nucleus and red indicates microtubule. Scale bars = 20 μm. G, H The mRNA (G) and protein (H) expression of TTK in two EC cell lines and a normal cell line EM were investigated using qRT-PCR and western blotting. ***P < 0.001, by Student’s t-tests

Back to article page